CA2666293C - Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders - Google Patents

Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders Download PDF

Info

Publication number
CA2666293C
CA2666293C CA2666293A CA2666293A CA2666293C CA 2666293 C CA2666293 C CA 2666293C CA 2666293 A CA2666293 A CA 2666293A CA 2666293 A CA2666293 A CA 2666293A CA 2666293 C CA2666293 C CA 2666293C
Authority
CA
Canada
Prior art keywords
sleep
night
dose
treatment
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2666293A
Other languages
English (en)
French (fr)
Other versions
CA2666293A1 (en
Inventor
Gunther Birznieks
Deepak Phadke
Mihael H. Polymeropoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2666293(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Priority to CA2950087A priority Critical patent/CA2950087A1/en
Publication of CA2666293A1 publication Critical patent/CA2666293A1/en
Application granted granted Critical
Publication of CA2666293C publication Critical patent/CA2666293C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CA2666293A 2006-05-22 2007-05-22 Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders Active CA2666293C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2950087A CA2950087A1 (en) 2006-05-22 2007-05-22 Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74784706P 2006-05-22 2006-05-22
US60/747,847 2006-05-22
PCT/US2007/069411 WO2007137244A1 (en) 2006-05-22 2007-05-22 Melatonin agonist treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2950087A Division CA2950087A1 (en) 2006-05-22 2007-05-22 Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders

Publications (2)

Publication Number Publication Date
CA2666293A1 CA2666293A1 (en) 2007-11-29
CA2666293C true CA2666293C (en) 2017-01-10

Family

ID=38723632

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2666293A Active CA2666293C (en) 2006-05-22 2007-05-22 Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders
CA2950087A Abandoned CA2950087A1 (en) 2006-05-22 2007-05-22 Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2950087A Abandoned CA2950087A1 (en) 2006-05-22 2007-05-22 Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders

Country Status (17)

Country Link
US (6) US20090105333A1 (ja)
EP (1) EP2028937B2 (ja)
JP (5) JP2009538332A (ja)
KR (2) KR101587394B1 (ja)
AU (3) AU2007253701A1 (ja)
BR (1) BRPI0712206A2 (ja)
CA (2) CA2666293C (ja)
CY (1) CY1120433T1 (ja)
DK (1) DK2028937T4 (ja)
ES (1) ES2532849T5 (ja)
MX (1) MX2008014841A (ja)
NL (1) NL300795I2 (ja)
PL (1) PL2028937T5 (ja)
PT (1) PT2028937E (ja)
RU (1) RU2488392C2 (ja)
WO (1) WO2007137244A1 (ja)
ZA (1) ZA200809529B (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855241B2 (en) 2012-01-26 2018-01-02 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105333A1 (en) † 2006-05-22 2009-04-23 Gunther Birznieks Melatonin agonist treatment
US11060144B2 (en) * 2007-09-13 2021-07-13 Vanda Pharmaceuticals Inc. Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
EP2453891A1 (en) * 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
MX2015007909A (es) * 2012-12-18 2016-04-25 Vanda Pharmaceuticals Inc Tratamiento de trastornos del ritmo circadiano.
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA3124872A1 (en) 2014-09-02 2016-03-10 Vanda Pharmaceuticals Inc. Tasimelteon for regulating melatonin production
EP3661494B8 (en) 2017-08-02 2023-11-22 Vanda Pharmaceuticals Inc. Use of tasimelteon for the treatment of affective disorders in majority black african patients
KR20240007693A (ko) * 2018-03-04 2024-01-16 반다 파마슈티칼즈, 인코퍼레이티드. 타시멜테온을 이용한 질환의 치료
JP7432884B2 (ja) * 2018-03-26 2024-02-19 パナソニックＩｐマネジメント株式会社 サポートシステム、機器制御システム、サポートシステムの作動方法、及び、機器制御システムの作動方法
US20210353586A1 (en) * 2018-09-12 2021-11-18 Vanda Pharmaceuticals Inc. Improving Sleep or Post-Sleep Performance
JP7139534B2 (ja) * 2019-02-13 2022-09-20 バンダ・ファーマシューティカルズ・インコーポレイテッド 睡眠の改善方法
AU2020299168B2 (en) * 2019-06-29 2024-05-09 Vanda Pharmaceuticals Inc. Tasimelteon use in treating sleep aberrations
WO2021119456A1 (en) * 2019-12-13 2021-06-17 Vanda Pharmaceuticals Inc. Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US5242941A (en) † 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
WO1996027658A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
BR9713690B1 (pt) * 1996-12-10 2009-08-11 agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano.
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US20050164987A1 (en) * 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality
KR101187461B1 (ko) * 2005-07-29 2012-10-02 반다 파마슈티칼즈, 인코퍼레이티드. 각성을 향상시키는 방법
US20090105333A1 (en) † 2006-05-22 2009-04-23 Gunther Birznieks Melatonin agonist treatment
EP3620794A1 (en) * 2012-01-26 2020-03-11 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
JP6921534B2 (ja) * 2014-02-12 2021-08-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高純度医薬品等級タシメルテオン
US20170326153A1 (en) † 2014-10-28 2017-11-16 Sandoz Ag Pharmaceutical Composition Consisting of Ceftaroline Fosamil Acetic Acid Solvate Particles Arginine Particles, Both Having A Specific Particle Size Distribution

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855241B2 (en) 2012-01-26 2018-01-02 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10149829B2 (en) 2012-01-26 2018-12-11 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10449176B2 (en) 2012-01-26 2019-10-22 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10610510B2 (en) 2012-01-26 2020-04-07 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10945988B2 (en) 2012-01-26 2021-03-16 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11285129B2 (en) 2012-01-26 2022-03-29 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11633377B2 (en) 2012-01-26 2023-04-25 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11826339B2 (en) 2012-01-26 2023-11-28 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11833130B2 (en) 2012-01-26 2023-12-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11850229B2 (en) 2012-01-26 2023-12-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918556B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders

Also Published As

Publication number Publication date
PT2028937E (pt) 2015-04-09
JP2018109057A (ja) 2018-07-12
US20090105333A1 (en) 2009-04-23
RU2488392C2 (ru) 2013-07-27
JP6659072B2 (ja) 2020-03-04
BRPI0712206A2 (pt) 2012-03-13
JP6480050B2 (ja) 2019-03-06
WO2007137244A1 (en) 2007-11-29
JP2019089812A (ja) 2019-06-13
AU2021273588B2 (en) 2023-03-02
ES2532849T5 (es) 2018-10-18
ES2532849T3 (es) 2015-04-01
US20230021493A1 (en) 2023-01-26
JP6306114B2 (ja) 2018-04-04
KR20090034810A (ko) 2009-04-08
US20160354337A1 (en) 2016-12-08
KR20150083932A (ko) 2015-07-20
CA2666293A1 (en) 2007-11-29
JP2009538332A (ja) 2009-11-05
RU2008150622A (ru) 2010-06-27
AU2021273588A1 (en) 2021-12-16
ZA200809529B (en) 2009-12-30
US20180243258A1 (en) 2018-08-30
EP2028937A4 (en) 2010-06-02
AU2013207585B2 (en) 2016-04-28
EP2028937A1 (en) 2009-03-04
CY1120433T1 (el) 2019-07-10
MX2008014841A (es) 2008-12-05
EP2028937B1 (en) 2015-01-28
DK2028937T3 (en) 2015-04-07
AU2007253701A1 (en) 2007-11-29
CA2950087A1 (en) 2007-11-29
KR101587394B1 (ko) 2016-01-21
US20200397741A1 (en) 2020-12-24
PL2028937T3 (pl) 2015-10-30
DK2028937T4 (en) 2018-09-03
PL2028937T5 (pl) 2018-12-31
US20150080464A1 (en) 2015-03-19
EP2028937B2 (en) 2018-06-27
JP2015013875A (ja) 2015-01-22
NL300795I2 (ja) 2017-03-28
KR101571163B1 (ko) 2015-11-23
JP2017031183A (ja) 2017-02-09

Similar Documents

Publication Publication Date Title
AU2021273588B2 (en) Melatonin agonist treatment
US20120136050A1 (en) Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
US8076315B2 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
Palatini Elevated heart rate in cardiovascular diseases: a target for treatment?
CA3075719A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
Amano et al. Prostaglandin inhibition and cerebrovascular control in patients with headache
AU2019250266A2 (en) Melatonin agonist treatment
WO2007047575A2 (en) Pharmacological treatments for sleep-related breathing disorders
KR20070011329A (ko) 인슐린 저항성 개선제를 함유하는 당뇨병 치료제
JP2021517910A (ja) タシメルテオンを用いる障害の治療
JP2005154368A (ja) ジソピラミド含有神経因性疼痛の鎮痛剤

Legal Events

Date Code Title Description
EEER Examination request